Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Gastric Cancer
Interventions
DRUG

DOCETAXEL

50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.

DRUG

S-1

80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.

DRUG

OXALIPLATIN

100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY